Today BMO Capital Reiterates a Outperform Rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and a $125 Target Price

February 24, 2018 - By Rodney Autry

 Today BMO Capital Reiterates a Outperform Rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and a $125 Target Price

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.13, from 1.26 in 2017Q2. It turned negative, as 40 investors sold BioMarin Pharmaceutical Inc. shares while 116 reduced holdings. 45 funds opened positions while 132 raised stakes. 171.51 million shares or 2.04% more from 168.09 million shares in 2017Q2 were reported.

Bluecrest Capital Mgmt Limited reported 5,347 shares. Proshare Ltd Com reported 158,808 shares stake. 72,580 are held by Apg Asset Management Nv. 148,157 were accumulated by Guggenheim Cap Lc. New York-based Orbimed Limited Liability Corporation has invested 0.66% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Perigon Wealth Mgmt Limited Liability Company reported 2,169 shares. Gp has invested 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Waddell Reed invested 0.49% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Alliancebernstein Lp owns 117,060 shares or 0.01% of their US portfolio. Old Mutual Customised Solutions (Proprietary) Ltd holds 0.06% or 5,110 shares in its portfolio. Citigroup Inc reported 32,783 shares. Nicholas Invest Ptnrs L P holds 37,829 shares. M&T Savings Bank Corporation owns 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 13,580 shares. Efg Asset (Americas) invested 0.26% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Comerica Bank & Trust has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 7,321 shares.

Since September 15, 2017, it had 0 buys, and 10 selling transactions for $9.95 million activity. $342,225 worth of stock was sold by LAWLIS V BRYAN on Friday, September 15. On Thursday, February 15 the insider BIENAIME JEAN JACQUES sold $846,285. Ajer Jeffrey Robert sold $334,495 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, September 22. HERON ELAINE J also sold $71,116 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, December 14. Another trade for 15,000 shares valued at $1.36M was sold by FUCHS HENRY J. Another trade for 30,000 shares valued at $2.72M was sold by Davis George Eric.

Biomarin Pharmaceutical (NASDAQ:BMRN) Rating Reaffirmed

New York: In analysts note released on Friday morning, BMO Capital maintained their Outperform rating on Biomarin Pharmaceutical (NASDAQ:BMRN) shares. They now have a $125 price target on the company. BMO Capital’s target means a potential upside of 50.51 % from the company’s current price.

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.13, from 1.26 in 2017Q2. It turned negative, as 40 investors sold BioMarin Pharmaceutical Inc. shares while 116 reduced holdings. 45 funds opened positions while 132 raised stakes. 171.51 million shares or 2.04% more from 168.09 million shares in 2017Q2 were reported.

Bluecrest Capital Mgmt Limited reported 5,347 shares. Proshare Ltd Com reported 158,808 shares stake. 72,580 are held by Apg Asset Management Nv. 148,157 were accumulated by Guggenheim Cap Lc. New York-based Orbimed Limited Liability Corporation has invested 0.66% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Perigon Wealth Mgmt Limited Liability Company reported 2,169 shares. Gp has invested 0% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Waddell Reed invested 0.49% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Alliancebernstein Lp owns 117,060 shares or 0.01% of their US portfolio. Old Mutual Customised Solutions (Proprietary) Ltd holds 0.06% or 5,110 shares in its portfolio. Citigroup Inc reported 32,783 shares. Nicholas Invest Ptnrs L P holds 37,829 shares. M&T Savings Bank Corporation owns 0.01% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 13,580 shares. Efg Asset (Americas) invested 0.26% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Comerica Bank & Trust has 0% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 7,321 shares.

Since September 15, 2017, it had 0 buys, and 10 selling transactions for $9.95 million activity. $342,225 worth of stock was sold by LAWLIS V BRYAN on Friday, September 15. On Thursday, February 15 the insider BIENAIME JEAN JACQUES sold $846,285. Ajer Jeffrey Robert sold $334,495 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Friday, September 22. HERON ELAINE J also sold $71,116 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Thursday, December 14. Another trade for 15,000 shares valued at $1.36M was sold by FUCHS HENRY J. Another trade for 30,000 shares valued at $2.72M was sold by Davis George Eric.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Among 27 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. BioMarin Pharmaceutical has $175 highest and $89 lowest target. $117.29’s average target is 41.23% above currents $83.05 stock price. BioMarin Pharmaceutical had 83 analyst reports since August 5, 2015 according to SRatingsIntel. Raymond James initiated BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, September 1 with “Outperform” rating. The rating was maintained by RBC Capital Markets on Friday, February 26 with “Outperform”. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Tuesday, July 18 by Leerink Swann. Morgan Stanley maintained the stock with “Overweight” rating in Friday, October 6 report. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Neutral” rating by Wedbush on Tuesday, September 1. The firm has “Outperform” rating by BMO Capital Markets given on Friday, October 27. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Robert W. Baird on Tuesday, October 3. The stock has “Outperform” rating by Leerink Swann on Tuesday, February 23. The rating was initiated by BMO Capital Markets with “Outperform” on Thursday, April 7. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Buy” rating given on Thursday, December 8 by Gabelli.

The stock decreased 1.13% or $0.95 during the last trading session, reaching $83.05. About 2.13 million shares traded or 63.81% up from the average. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since February 24, 2017 and is uptrending. It has underperformed by 11.41% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company has market cap of $14.59 billion. The Company’s commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria , an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. It currently has negative earnings. The firm also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB.

More notable recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Livetradingnews.com which released: “BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Heffx Trading Review” on February 05, 2018, also Zacks.com with their article: “BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat” published on February 23, 2018, Benzinga.com published: “Biomarin Pharmaceutical Q4 Earnings Outlook” on February 22, 2018. More interesting news about BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were released by: Benzinga.com and their article: “Why Leerink Adjusted Upside Expectations For 3 Biotechs” published on February 23, 2018 as well as Seekingalpha.com‘s news article titled: “BioMarin Pharmaceutical (BMRN) Q4 2017 Results – Earnings Call Transcript” with publication date: February 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.